Joon Kim, MD
Ophthalmology · Morrow, GANPI 1942295233
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $803 and has fallen 66.4% since, to $270 in 2025.
Across 64 payments — averaging $37.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$547
- Amgen$321
- Eyepoint US, Inc.$250
- Alcon Research LLC$141
- Bausch & Lomb Americas Inc.$128
- Alimera Sciences, Inc.$127
- plus $916 from 20 others
Across 15 payments — averaging $1547.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$23K
What the payments were for
- Travel & lodging$121%
- Food & beverage$2,41999%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 13 | $547 |
| Amgen(2 entities) | 4 | $321 |
| Eyepoint US, Inc. | 2 | $250 |
| Alcon Research LLC | 1 | $141 |
| Bausch & Lomb Americas Inc. | 6 | $128 |
| Alimera Sciences, Inc. | 1 | $127 |
| Novartis | 7 | $114 |
| Pfizer | 1 | $112 |
| Harrow Eye, LLC | 3 | $83 |
| AbbVie | 3 | $74 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $68 |
| NEW World Medical,inc. | 1 | $45 |
| Rxsight Inc | 1 | $43 |
| Kala Pharmaceuticals, Inc. | 2 | $42 |
| Sun Pharmaceutical Industries Inc. | 2 | $41 |
| Sight Sciences, Inc. | 2 | $39 |
| Dompe US, Inc. | 1 | $24 |
| Ocular Therapeutix, Inc. | 1 | $24 |
| Tarsus Pharmaceuticals, Inc. | 1 | $24 |
| Shire North American Group Inc | 1 | $21 |
| Thea Pharma Inc. | 1 | $20 |
| Eyevance Pharmaceuticals LLC | 1 | $19 |
| Oyster Point Pharma, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,431 in reported general payments places this provider in the 55th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IlevroNepafenac | 86 | $31,986 |
| Lotemax SmLoteprednol Etabonate | 107 | $27,569 |
| ProlensaBromfenac Sodium | 61 | $21,120 |
| BesivanceBesifloxacin Hcl | 52 | $11,753 |
| Bromfenac Sodium | 49 | $8,879 |
| Prednisolone Acetate | 47 | $1,403 |
| MoxifloxacinMoxifloxacin Hcl | 40 | $1,032 |
| Ketorolac Tromethamine | 55 | $896 |
| Latanoprost | 15 | $267 |
| Ofloxacin | 20 | $242 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa, Besivance | $68 | $60,443220 claims |
| NovartisIlevro | $114 | $31,98686 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Morrow
- Harvey DubinerMorrow$31K
- Gagan SawhneyAtlanta$582K
- Lawrence WoodardAtlanta$578K
- Stephanie VanderveldtAtlanta$384K
- Steven YehAtlanta$289K
- Jack ChapmanGainesville$244K
- Gregory LeeCumming$214K
- Puneet PandaMarietta$185K
- Jeffrey TranSuwanee$150K
- Evan SchoenbergAtlanta$130K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.